CRISPR Therapeutics vs Emendo Biotherapeutics
CRISPR Therapeutics vs Emendo Biotherapeutics, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CRISPR Therapeutics is on 64/100 and Emendo Biotherapeutics on 59/100.
Where each one leads
CRISPR Therapeutics
- our overall score: 64/100 against 59/100
- domain rating: 67/100 against 20/100
- funding raised: $547M against $61.0M
Emendo Biotherapeutics
Leads on none of the measures we hold for both companies.
At a glance
| Measure | CRISPR Therapeutics | Emendo Biotherapeutics |
|---|---|---|
| What it is | Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology. | Developing genetic medicines and cell therapies for severe diseases using proprietary CRISPR OMNI technology. |
| Category | Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals | Healthcare, Genome Editing, CRISPR, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2013 | 2015 |
| Headquarters | Zug, Switzerland | Tel Aviv, Israel |
| Status | Active | Active |
Size, funding and growth
| Measure | CRISPR Therapeutics | Emendo Biotherapeutics |
|---|---|---|
| Employees | Not published | 41 |
| Headcount growthLast 12 months | Not published | -16.1% |
| Total funding | $547M | $61.0M |
| Latest round | Series B | Series B |
| LinkedIn followers | Not published | 5,333 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CRISPR Therapeutics | Emendo Biotherapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 59/100 |
| Traction | 40/100 | 55/100 |
| Team | 70/100 | 40/100 |
| Search visibility | 13/100 | 44/100 |
| Quality | 88/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (44/100) | D (40/100) |
| Domain ratingLink authority, 0-100 | 67/100 | 20/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CRISPR Therapeutics | Emendo Biotherapeutics |
|---|---|---|
| Hosting | Self Managed | Google Cloud |
| CMS | Not detected | WordPress |
| Frameworks | Jquery | Bootstrap |
| Analytics | Google Analytics 4 | Google Tag Manager |
CRISPR Therapeutics vs Emendo Biotherapeutics: common questions
Which is better, CRISPR Therapeutics or Emendo Biotherapeutics?
On our 0-100 score CRISPR Therapeutics rates higher (64/100 against 59/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do CRISPR Therapeutics and Emendo Biotherapeutics compare on the numbers?
CRISPR Therapeutics leads on our overall score (64/100 against 59/100), domain rating (67/100 against 20/100), funding raised ($547M against $61.0M).
Read the full CRISPR Therapeutics review and pricing or the Emendo Biotherapeutics review and pricing. You can also browse other CRISPR Therapeutics alternatives we track.